Candesartan cilexetil in cardiovascular disease

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 6, 2004, Pages 829-835

  Ross, Amy ^a   Papademetriou, Vasilios ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Angiotensin receptor blocker; Candesartan; Heart failure; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LITHIUM; LOSARTAN; NIFEDIPINE; OLMESARTAN; ORAL CONTRACEPTIVE AGENT; PLACEBO; SPIRONOLACTONE; TELMISARTAN; VALSARTAN; WARFARIN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DIABETIC NEPHROPATHY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; INSULIN SENSITIVITY; KIDNEY DYSFUNCTION; MONOTHERAPY; OBESITY; PERIPHERAL EDEMA; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE; SYMPTOMATOLOGY; SYSTOLIC HYPERTENSION;

EID: 8644219603     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.6.829     Document Type: Article

References (31)

1. American Heart Association. Heart disease and stroke statistics - 2003 update. American Heart Association TX, USA (2002).
2. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute (NHLBI) - National Institutes of Health (3)5233 (2003).
3. Psaty BM, Furberg CD, Kuller LH et al. Association between blood pressure level and the risk of myocardial infarction, stroke and total mortality: the cardiovascular health study. Arch. Intern. Med. 161, 1183-1192 (2001)
4. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am. Heart. J. 141, 334-341 (2001).
5. Coresh J, Wei GL, McQuillan G et al. Prevalence of high blood pressure and elevated serum creatinine level in the USA: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch. Intern. Med. 161, 1207-1216 (2001).
6. Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am. J. Hypertens. 7(7 Pt 2), S7-S12 (1994).
7. Hajjar I, Kotchen TA. Trends in Prevalence, awareness, treatment, and control of hypertension in the USA, 1988-2000. J. Am. Med. Assoc. 290, 199-206 (2003).
8. Stroth U, Unger T. The renin-angiotensin system and its receptors. J. Cardiovasc. Pharmacol. 33(Suppl. 1) S21-S28 (1999).
9. Black H. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data. Am. Heart J. 147(4), 564-572 (2004).
10. Burnier M. Angiotensin II Type 1 receptor blockers. Circulation 103(6), 904-912 (2001).
11. Reif M, White, W, Fagan T et al. Effects of candesartan cilexetil in patients with systemic hypertension. Am. J. Cardiol. 82(8), 961-965 (1998).
12. Bakris G. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J. Clin. Hypertens. 3(1), 16-21 (2001).
13. Belz G, Butzer R, Kober S, Mutschler E. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans. J. Cardiovasc. Pharmacol. 39(4), 561-568 (2002).
14. Contreras F, Cabrera J, Ospino N, Israili Z, Velasco M. Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension. Am. J. Therapeut. 10(6), 401-408, (2003).
15. Sever P. Clinical profile of the novel angiotensin II Type I blocker candesartan cilexetil. J. Hypertens. 15 (Suppl. 6), S9-S12 (1997).
16. Kloner RA, Weinberger M, Poole JL et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Am J. Cardiol. 87, 727-731 (2001).
17. Eguchi K. Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. Am. J. Cardiol. 92(5), 621-624 (2003).
18. Andersson O, Neldam S. Candesartan cilexetil 16 mg provides greater antihypertensive effect than losartan 50 mg in patients with mild-to-moderate hypertension. Am. J. Hypertens. 9(Suppl. 1), 55 (2000).
19. Papademetriou V, Reif M, Henry D et al. Combination therapy with candesartan cilexetil and hydrochlorothiazide in patients with systemic hypertension. J. Clin. Hypertens. 2(6), 372-378 (2000).
20. Papademetriou V, Narayan P, Kikkinos P. Angiotenin-converting enzyme and angiotensin receptor blockers in hypertensive African Americans. J. Clin. Hypertens. 6, 310-314 (2004).
21. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial, CHARM-Added, CHARM-preserved. Lancet 362(9386), 767-781 (2003).
22. Jacobsen P, Rossing K, Parving HH. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Curr. Opin. Nephrol. Hypertens. 13(3), 319-324, (2004).
23. Mogensen CE, Neldam S, Tikkanen I et al., for the CALM study group. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin-dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) study. Br. Med. J. 321, 1440-1444 (2000).
24. Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation 76(8 , 1170-1174 (2003).
25. Grassi G, Seravalle G, Dell'Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J. Hypertens. 21(9), 1761-1769 (2003).
26. Lithell H, Hansson L, Skoog I et al., for the SCOPE Study Group. The Study on COgnition and Prognosis in the Elderly (SCOPE): principal results of a randomized, double-blind, intervention trial. J. Hypertens. 21(5), 875-886 (2003).
27. Schrader J, Luders S, Kulschewsk A et al., on behalf of the ACCESS Study Group. The ACCESS study: evaluation of Acute Candesartan Cilexetil thErapy in Stroke Survivors. Stroke 34(7), 1699-1703 (2003).
28. Kondo J, Sone T, Tsuboi H. Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Am. Heart J. 146(6), E20 (2003).
29. Ram C, Fenves A. Clinical pharmacology of antihypertensive drugs. Cardiol. Clin. 20(2), 265-280 (2002).
30. Bakris G, Gradman A, Reif M et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J. Clin. Hypertens. 3(1), 16-21 (2001).
31. Vauquelin G, Fierens FL, De Backer JP, Vanderheyden PM. The effects of candesartan on human AT1 receptor-expressing Chinese hamster ovary cells. J. Am. Soc. Nephrol. 10(Suppl 11), S15-S17 (1999).